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Objective: To evaluate the efﬁcacy of a single intra-articular (IA) dose of FX006, an extended-release
formulation of triamcinolone acetonide (TCA) in poly(lactic-co-glycolic acid) (PLGA) microspheres, on the
sequelae of repeated episodes of synovitis.
Design: Three ﬂares of localized synovitis in the right knee of rats were induced over 4 weeks following a
single IA injection of various doses of FX006, Kenalog® (TCA immediate release or TCA IR), or vehicle. Gait
scores were employed to assess analgesic effect, and the joints were evaluated by histology at the end of
the study. TCA plasma concentrations and corticosterone levels were monitored through the study.
Results: A single IA dose of 0.28 mg FX006 signiﬁcantly improved gait scores through all three reac-
tivations. TCA IR at 0.06 mg (providing comparable plasma TCA exposure, 10-fold higher Cmax)
demonstrated comparable beneﬁt through the ﬁrst reactivation only and reduced-to-no efﬁcacy there-
after. Signiﬁcantly improved histological joint scores were observed with effective doses of FX006 but
not with TCA IR. Corticosterone levels were initially decreased following both TCA IR and FX006 treat-
ment, but recovered by Day 14.
Conclusions: In localized, repeated synovitis in rats, sustained release of TCA following a single IA in-
jection of FX006 signiﬁcantly prolonged analgesia relative to TCA IR and signiﬁcantly improved histo-
logical scores with no adverse effect on the HPA axis. Since synovitis can contribute to the
pathophysiology of multiple joint diseases such as osteoarthritis (OA), RA and gout, FX006 may be an
important treatment option for these conditions.
© 2014 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Synovial inﬂammation contributes to the underlying pathology
of a number of disease states including gouty arthritis, psoriatic
arthritis; rheumatoid arthritis, and juvenile rheumatoid arthritis.
While osteoarthritis (OA) has historically been considered a non-
inﬂammatory condition, recent literature suggests that synovitis
is present in all stages of knee OA1e3 and correlates to both the
occurrence of symptoms4e8 and structural progression9e14. In OA,
available evidence suggests that synovial inﬂammation produces: A. Kumar, Nonclinical R&D
, MA 01803, USA. Tel: 1-781-
com (A. Kumar), alison@
com (R.C. Blanks), nbodick@
ternational. Published by Elsevier Lproinﬂammatory cytokines such as IL-1 and TNF-a that may reduce
secretion of lubricin15,16 and mediate cartilage damage through
activation of metalloproteinases17e22.
Intra-articular (IA) administration of immediate release (sus-
pension) corticosteroids, including triamcinolone acetonide (TCA),
has been routine in the management of knee OA for decades.
However, inwell-controlled studies, IA corticosteroids demonstrate
a duration of effect of only 1e3 weeks23e25. FX006 has been
developed to extend the duration of effect of TCA in patients with
OA of the knee. FX006 is formulated for IA injection and contains
TCA, USP, formulated in 75:25 poly(lactic-co-glycolic acid) (PLGA)
microspheres with a nominal drug load of 25% (w/w).
Poly(lactide-co-glycolic acid) is a biodegradable co-polymer of
poly-lactide and poly-glycolide that in vivo is gradually degraded to
carbon dioxide and water. It is widely regarded as biocompatible
and several injectable sustained-release microsphere and other
implantable PLGA drug products and devices have been approved
for commercial use26. The prolonged release of TCA from PLGAtd. All rights reserved.
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anti-inﬂammatory effects relative to TCA IR, and avoid the high
peak plasma TCA concentrations associated with TCA IR. The
objective of the current study was to test this hypothesis in a rat
model of localized, repeated synovitis which contributes to several
joint diseases including many patients with OA.
Methods
FX006
FX006 contains TCA, USP, formulated in 75:25 poly(lactic-co-
glycolic acid) (PLGA) microspheres with a nominal drug load of
25% (w/w) and is provided as a sterile white-to-off-white powder
for reconstitution. The drug product is reconstituted with diluent
containing an isotonic, sterile aqueous solution of sodium chloride
(NaCl; 0.9%w/w), carboxymethylcellulose sodium (CMC; 0.5%w/w)
and polysorbate-80 (0.1% w/w) to form a suspension prior to IA
injection. The microspheres range in size from 20 to 100 mm
(median ¼ 42 mm).
Animal model development
A new OA-like model was developed in rats wherein localized
monoarticular arthritis/synovitis was induced in the right knee of
Male Lewis rats27,28. Following a priming IA injection of strepto-
coccal cell wall peptidoglycan polysaccharide (PGPS; 100P fraction
with 5e8 mg rhamnose/mL from Lee Laboratories) repeated epi-
sodes of synovitis in the right knee were induced by administering
PGPS intravenously.
Male Lewis rats weighing 242e265 g at initial randomization
by body weight (Day 18) were obtained from Charles River
Laboratories, Inc., Wilmington, MA and housed 5 to a cage. The
study design was approved by Bolder BioPATH's Institutional
Animal Care and Use Committee (IACUC), Boulder, CO. Animals
were acclimated for 10 days prior to being placed on study. An
attending veterinarian was on site or on call during the live phase
of the study. No concurrent medications were given. Housing of
the animals throughout the study conformed to the guidelines
cited in the Guide for the Care and Use of Laboratory Animals and
the applicable standard operating procedures of Bolder BioPATH,
Inc.
A timeline of study procedures is presented in Fig. 1.
On Day 18, following anesthesia with 3% isoﬂurane, the right
knees of rats were sensitized/primed by IA injection of PGPS (50 mL
of 0.125 mg/mL). The day after IA sensitization, animals with no
knee discomfort were eliminated from the test article groups and
placed into the baseline group. Baseline assessments were per-
formed on Day 3 and animals were re-randomized based on theFig. 1. The timeline of study procedures and assessments is sdegree of pain/swelling (assessed as below) to ensure similar
weight-bearing deﬁciency across treatment groups. On Day
0 (twoþ weeks following sensitization) when the acute phase of
inﬂammation had passed, a tail vein injection of PGPS (0.5 mL of
0.4 mg/mL) was administered to reactivate knee inﬂammation and
local right knee pain. Flares were similarly induced again on Days
14 and 28. In this manner, synovitis/arthritis was kept localized to
the right knee in rats. Ankle swelling was monitored using calipers
in the animals to check for spreading of the inﬂammatory
response and loss of localization to the right knee. It was possible
to keep synovitis/arthritis localized for three reactivation epi-
sodes, 2 weeks apart for a total duration of just over a month (32
days). TCA IR (Kenalog-40®) was purchased from Bristol-Myers
Squibb. FX006 (25% TCA in 75:25 PLGA microspheres) was pro-
vided by Flexion Therapeutics as a powder that was refrigerated
until reconstitution in diluent (sterile aqueous solution of sodium
chloride (NaCl; 0.9% w/w), sodium carboxymethylcellulose
(NaCMC 0.5% w/w) and polysorbate-80 (0.1% w/w)). Diluent,
FX006 or TCA IR was administered in the index knee by a single IA
injection 2.5 h prior to the ﬁrst reactivation of arthritis/synovitis
by PGPS on Day 0 (n ¼ 10/group; 2 cages/group based on pilot
studies performed earlier). Differences in weight-bearing and gait
(as a measure of joint pain experienced by the animals), plasma
pharmacokinetics and pharmacodynamics (hypothalamus-pitui-
tary-adrenal (HPA) axis effect) of TCA were characterized to
compare the efﬁcacy of a single IA dose of FX006 with TCA IR. The
duration of efﬁcacy of single IA doses of FX006 or TCA IR, (each
given only once before the ﬁrst reactivation on Day 0) was
assessed by scoring joint pain/impaired gait, before and 1, 2 and 4
days following each reactivation (ﬂare of synovitis/arthritis) e
reactivations performed on Days 0,14 and 28; pain assessments on
Days 3 (before ﬁrst reactivation), 1, 2, 4, 14 (before second
reactivation), 15, 16, 18, 28 (before third reactivation), 29, 30, 32.
After that point, the arthritis observed in the animals become
more wide-spread (monitored by ankle swelling) making the
attribution of pain to the index knee more difﬁcult. Hence, this
protocol allowed for prolonged assessment of the efﬁcacy of single
IA doses of FX006 and TCA IR through Day 32 when the experi-
ment was terminated and the knee joints were collected for
evaluation by histopathology.
Dose selection
Pharmacokinetics and effects on HPA axis function (cortisol
suppression) for a range of doses of FX006 and TCA IR were eval-
uated in a separate study of Male Lewis rats to assist in dose se-
lection for the present study. Following IA administration of
0.28 mg of FX006 in that study, cortisol levels returned to baseline
within 14 days of administration, a pattern of cortisol suppressionhown in the schematic above and described in the text.
Table II
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of TCA IR29 at doses that are considered effective andwell tolerated.
The doses of FX006 were selected to be 0.28, 0.12 or 0.03 mg TCA.
Data from this study also suggested that TCA IR at a dose of 0.06 mg
would provide overall systemic TCA exposure comparable to that of
FX006 at a dose of 0.28 mg (approximately 350 h ng/mL). This dose
of TCA IR also produced approximately the same maximum plasma
TCA concentration as the labeled dose of 40 mg IA injection of TCA
IR in humans (Cmax ~12 ng/ml)29. Initial dose-range ﬁnding exper-
iments in the localized knee arthritis rat model also suggested that
a dose of TCA IR of 0.06 mgwould have a duration of efﬁcacy of 1e3
weeks matching the duration of effect observed in clinical
practice23e25. The selected doses of TCA IR were 0.06 or 0.03 mg
FX006, TCA IR or vehicle (diluent; control animals) were all
administered as single IA injections in the sensitized right knee
2.5 h prior to the ﬁrst reactivation of arthritis/synovitis by PGPS on
Day 0.0 Normal
0.5 Score reserved for those that are normal on low magniﬁcation but
have the earliest hint of small focal areas of resorption in a marginal
zone
1 Minimal; small deﬁnite areas of resorption in marginal zones only
2 Mild; Small areas of resorption in marginal zones and extending up
to 1/4 of the distance across the affected surface
3 Moderate; areas of resorption extend beyond marginal zones >1/4
but less than 1/2 of the subchondral surface
4 Marked; areas of resorption extend beyondmarginal zones>1/2 but
less than 3/4 of the subchondral surface
5 Severe; areas of resorption extend beyond marginal zones >3/4 ofAssessment of pain (Gait Scores)
Gait analysis was performed by applying black ink to the ventral
surface of the rear feet of all rats and allowing them to walk the full
length of a sheet of paper. Animals were observed visually and
footprints made by the right injected leg were compared with the
left uninjected one to assess weight bearing duringmovement. Gait
was scored as shown in Table I.the subchondral surface
Inﬂammation
0 Normal
0.5 Minimal generally focal inﬁltration of inﬂammatory cells in
synovium
1 Minimal diffuse inﬁltration of inﬂammatory cells in synovium
2 Mild diffuse inﬁltration of inﬂammatory cells in synovium and
extending into periarticular tissues
3 Moderate diffuse inﬁltrationwithmoderate edema in synovium and
extending into periarticular tissues
4 Marked diffuse inﬁltration with marked edema in synovium and
extending into periarticular tissuesHPA axis function (corticosterone levels)
Serum corticosterone levels were measured following morning
blood collections via the tail vein in samples taken at baseline
(Day 4), Day 0 (2 h post-dose with vehicle, FX006 or TCA IR, just
prior to reactivation with PGPS), then Days 3, 14, 17, 28 and 31. A
Mouse and Rat Corticosterone ELISA kit from Kamiya Biomedical
Companywas used in accordancewith provided instructions with a
1:40 dilution.5 Severe diffuse inﬁltration with severe edema in synovium and
extending into periarticular tissues
Pannus
0 Normal
0.5 Minimal, focal or only few marginal zones affected
1 Minimal inﬁltration of pannus in cartilage and subchondral bone,
primarily affects marginal zones
2 Mild inﬁltration (<1/4 of tibia or tarsals at marginal zones)
3 Moderate inﬁltration (1/4e1/3 of tibia or small tarsals affected at
marginal zones)
4 Marked inﬁltration (1/2e3/4 of tibia or tarsals affected at marginal
zones)
5 Severe inﬁltration (>3/4 of tibia or tarsals affected at marginalPlasma pharmacokinetics
Blood samples in EDTA were collected at the same time points
utilized for the corticosterone assay and placed on crushed wet ice
until centrifugation. The resultant plasma was frozen immediately
over dry ice. Plasma TCA levels were measured using a qualiﬁed
bioanalytical LC-MS/MS assay. Non-compartmental pharmacoki-
netic analysis of concentration-time data was performed using
WinNonlin Version 5.3.Table I




0 Normal, equal ink staining on both feet
1 Slight limp, toe staining evident and some heel staining for all steps,
no carrying or dragging. If left has very little heel staining (rat walks
mainly on toes) then slightly (approximately 25%) less toe staining
in right leg vs left for most steps
2 Limping, toes only staining for all steps, no carrying or dragging. If
left has very little heel staining (rat walks mainly on toes) then
approximately 50% less toe staining in right leg vs left for most steps
3 Dragging and carrying leg, black drag marks from dorsal side of foot
present or some attempt to use right as evidenced by minimal toe
staining in at least one print, may pause and place right foot down
for a single step (or approximately 75% less staining on right vs left)
4 Carrying leg entire time, no staining from painful leg or only minor
black drag marks, no toe staining in any print (100% less staining on
right vs left)Histopathology
Following 5e7 days in 5% formic acid decalciﬁer, rat knees
were cut into two approximately equal halves and processed for
parafﬁn embedding and then stained with toluidine blue (for
glycosaminoglycans). Tissues were examined microscopically by
a board certiﬁed veterinary pathologist (Dr Alison Bendele) and
observations were entered into a computer-assisted data retrieval
system. Scoring of knee sections was performed as shown in
Table II.zones, severe distortion of overall architecture)
Cartilage damage
0 Normal
0.5 Minimal, focal or only few marginal zones affected
1 Minimal; minimal to mild loss of toluidine blue staining with no
obvious chondrocyte loss or collagen disruption, lesions mainly in
marginal zones
2 Mild; mild loss of toluidine blue staining with focal mild
(superﬁcial) chondrocyte loss and/or collagen disruption mainly in
marginal zones, may have 1e2 small areas of more severe
degeneration
3 Moderate; moderate loss of toluidine blue staining with multifocal
moderate (depth to middle zone) chondrocyte loss and/or collagen
disruption on at least one surface but still mainly in marginal zones,
may have 1e2 small areas of more severe degeneration
4 Marked; marked loss of toluidine blue staining with multifocal
marked (depth to deep zone or tidemark) chondrocyte loss and/or
collagen disruption on at least one surface
5 Severe; severe diffuse loss of toluidine blue staining with multifocal
severe (depth to tidemark) chondrocyte loss and/or collagen
disruption affecting more than two cartilage surfaces
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Data were analyzed using a one-way analysis of variance (nec-
ropsy data such as organweights and certain in-life measurements
such as ankle diameters) with a Dunnett's multiple comparison.
Gait and histopathology scores were evaluated using a Krus-
kaleWallis test (non-parametric) with appropriate Dunn's multiple
comparison post-test. ELISA data were evaluated by the Student's
t-test. Signiﬁcance for all tests was set at P  0.05.
Results
Assessment of pain/gait impairment
Upon the ﬁrst reactivation of arthritis, vehicle-treated control
animals demonstrated painful gait as demonstrated by high
(abnormal) scores (3.5 out of a maximum of 4) [Fig. 2(A) and (B)].
FX006 at 0.28 mg had good analgesic efﬁcacy as demonstrated by
near-normal gait scores on Days 1, 2 and 4 following the ﬁrst
reactivation [Fig. 2(A) and (B)]. After that, the animals accommo-
dated to the pain and the transient ﬂare of synovitis resolved.
Further assessments of efﬁcacy were similarly performed 1e4 days
after the two subsequent reactivations. The 0.28 mg dose of FX006
continued to be efﬁcacious following the second and third reac-
tivations on Days 15e18 and Days 29e32 by which time the HPA
axis function was normal [see accompanying corticosterone levels
Fig. 4(A)]. Animals injected with 0.06 mg of TCA IR on Day 0 (which
produces initial plasma concentrations approximately 10-fold that
observed with the 0.28 mg dose of FX006 and comparable overall
systemic TCA exposure) demonstrated signiﬁcant improvement in
gait scores through the ﬁrst reactivation, diminution of effect after
the second reactivation and absence of effect following the third
reactivation [Fig. 2(A) and (B)]. There were 10 rats/group at the
start. Gait data were excluded for animals that showed ankle
swelling e one animal in most groups at second reactivation and
1e7 animals across groups at third activation leading to study
termination at this point.
Overall, a clear dose-dependent analgesic response was noted
for both FX006 and TCA IR [Fig. 2(A)]. Further, the duration of ef-
ﬁcacy of TCA (single doses of either FX006 or TCA IR given before
the ﬁrst reactivation of arthritis) appeared to be a function of dose;
however, the prolonged release of TCA from the PLGAmicrospheres
in FX006 resulted in more sustained efﬁcacy than TCA IR.
Assessment of plasma concentrations of TCA
Plasma TCA concentration-time curves for all treatment groups
(n ¼ 5/group/time point) are shown in Fig. 3. IA FX006 provides a
slow, sustained and smooth TCA release, eliminating the early spike
in plasma concentration observed with TCA IR suspension. A
limited non-compartmental plasma pharmacokinetic analysis was
performed with these concentration data from the relatively small
number of time points that were samples from the study animals.
Mean peak plasma concentrations with FX006 at 0.28 mg were
about 10-fold lower than those achieved with TCA IR at 0.06 mg
(Cmax 1.68 vs 17.3 ng/mL; P  0.05). The corresponding overall
systemic TCA exposure at these doses was comparable (AUC0e∞
587 vs 324 h ng/mL).
Assessment of HPA axis effect of TCA
Corticosterone measurements in the study animals (as an indi-
cator of HPA axis function) were measured as change from baseline
for each treatment group at several time points (n ¼ 5/group/time
point) through the study [Fig. 4(A)]. In general the corticosteronedata in this study were more variable than were observed in the
separate study in normal healthy unmanipulated animals. The
increased variability is likely due to the pain and stress resultant for
the induced synovitis and study-related handling procedures. As
shown in Fig. 4(A), all treatment groups had similar corticosterone
levels at baseline, all were initially somewhat inhibited and all
groups recovered by Day 14. A PK-PD analysis demonstrated that
consistent with previously reported investigations in humans30,
inhibition of corticosterone was correlated with systemic TCA
levels (for both FX006 and TCA IR) in rats and followed a classical
inhibitory model as shown in Fig. 4(B) below. The IC50 in rats was
about 1 ng/mL which is also consistent with a previous report in
humans29. FX006 achieved prolonged analgesic efﬁcacy with a Cmax
of only 1.68 ng/mL at 0.28mg (highest dose) andwith no prolonged
inhibition of HPA axis function.
Assessment of joint structure
Histopathological evaluation of the index knees (n ¼ 2e7/group)
taken from vehicle-treated rats at the end of the study (Day 32; 4
days following the third and ﬁnal reactivation of synovitis) showed
marked-to-severe inﬂammation with minimal-to-moderate pannus
formation and cartilage damage, and mild bone resorption [Fig. 5(A)
and (B)]. The mean summed histopathology score (a composite of
the four individual parameters: inﬂammation, pannus, cartilage
damage, bone resorption) was 11 out of a possible 20. At the high
and mid dose (0.28 and 0.12 mg) FX006 demonstrated a statistically
signiﬁcant improvement in the composite histological score and
each component score relative to disease controls as shown in
Fig. 5(A) and (B). The extended duration of analgesic and presumably
anti-inﬂammatory efﬁcacy with FX006 resulted in a signiﬁcant
improvement in histological scores of joint tissues with scores
approximating normal tissue architecture at the high and mid dose
of FX006.
On the other hand, the 0.06 mg and the 0.03 mg doses of TCA IR
were associated with a smaller, non-signiﬁcant improvement in
histological scores as compared to diseased controls. It is noted that
the lowest dose of FX006, which was not as effective as the two
higher doses in this rat model, had a similar small, non-signiﬁcant
effect on histological score.
Representative photomicrographs of knee sections for a vehicle
control/diseased rat and rats treated with the highest doses of TCA
IR or FX006 at the end of the study following the third reactivation
of synovitis on Day 32 are shown in Fig. 6. Inﬁltration of inﬂam-
matory cells into the synovium, cartilage damage and bone
resorption were noted in the vehicle control animals (A). These
were also noted following TCA IR treatment (B) however, treatment
with a single IA dose of FX006 which achieved sustained analgesic
efﬁcacy also resulted in prevention of damage to the joint and
especially also to the cartilage such that these rats had near-normal
joints over the course of this study despite the induction and three
cycles of reactivation of synovitis (C).
Discussion
Synovitis contributes to the underlying pathology and joint
degeneration in a number of disease states such as rheumatoid
arthritis, juvenile rheumatoid arthritis, psoriatic arthritis, gouty
arthritis and OA. In OA, now described as a disease of the “whole
joint”, inﬂammatory mediators can be released from both syno-
viocytes and chondrocytes31 and dysregulation of complement has
also been demonstrated32. Suppression of synovial inﬂammation,
cytokine production and metalloproteinase synthesis with IA cor-
ticosteroids has the potential to reduce structural damage and limit
disease progression in inﬂammatory joint diseases including OA in
Fig. 2. Gait analysis scores (mean ± S.E.M.) are shown for control rats (black diamonds) and for rats treated with FX006 or TCA IR through three reactivations of localized synovitis/
arthritis (A) All treatment groups (B) Control animals and groups treated with the highest doses of FX006 (red squares) and TCA IR (purple open circles) that provide comparable
systemic exposure to TCA. A single IA injection of FX006 on Day 0, most notably at 0.28 mg, resulted in sustained analgesic efﬁcacy throughout the study period achieving statistical
signiﬁcance compared to vehicle control on Days 1, 2, 4, 15 and 16 (P  0.05 KruskaleWallis test with Dunn's multiple comparison post-test).
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could not only provide prolonged pain relief and functional
improvement, but also may limit structural progression in OA.
FX006 provides an extended and predictable release of TCA as
the biocompatible PLGA microspheres slowly degrade. A single IA
dose of FX006 results in less systemically bioavailable TCA when
compared to a matched dose of TCA IR on account of slower release
and absorption into the systemic circulation. By providing pro-
longed local exposure to TCA while minimizing systemic exposure,IA injection of FX006 is expected to have sustained anti-
inﬂammatory and analgesic efﬁcacy with minimal adverse effects.
In the present study, a localized rat model of knee arthritis with
synovitis was developed and validated using a dose of TCA IR that
demonstrated the short-term efﬁcacy of 1e3 weeks routinely
observed in the clinic23e25. This model allowed the evaluation of
the efﬁcacy of FX006, an extended-release IA formulation of TCA,
and comparison with the efﬁcacy proﬁle of TCA IR. The results
demonstrate a clear dose response for both TCA IR and FX006
Fig. 4. (A) Serum corticosterone levels (mean ± S.E.M.) are shown over time for vehicle-treate
clarity since the data were variable in these animals, likely on account of the pain and s
immediately following dose administration, recovered in all animals by 2 weeks. (B) Serum c
of plasma TCA concentration. This PK/PD analysis showed (red line) that HPA axis effects as
serum corticosterone was inhibited when plasma concentration was above 1 ng/mL.
Fig. 3. Mean plasma concentrations of TCA over time measured in animals treated
with FX006 or TCA IR are shown for all FX006 and TCA IR groups. Inset shows the low
TCA concentrations (mean ± S.E.M.) in the FX006 groups on a smaller scale.
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and anti-inﬂammatory efﬁcacy. Further, FX006 at 0.28 mg pro-
longed pain relief relative to TCA IR administered at a dose that
provided comparable systemic exposure to TCA. Histopathologic
evaluation extended the results from gait and weight-bearing an-
alyses, with signiﬁcantly better near-normal knee joints in rats that
received single doses of FX006 at 0.28 or 0.12 mg IA as compared to
vehicle-treated controls that showed signiﬁcant inﬂammation,
pannus formation, cartilage damage and bone resorption. Low dose
FX006 and TCA IR groups that did not have sustained anti-
inﬂammatory/analgesic activity through the duration of the study
(three reactivations of arthritis) also showed progression of the
histological lesion/joint disease in this model.
Corticosteroid treatment has been demonstrated to have a
protective effect on articular cartilage in models of in vitro struc-
tural/chemical damage35e37 and in animal models of inﬂammatory
arthritis and OA38e42. To provide a speciﬁc example, degenerative
cartilage changes following IA injection of sodium iodoacetate (a
chondrocyte metabolic inhibitor) include loss of staining with
Safranin O (indicating loss of glycosaminoglycans) in cartilage, and
depletion of chondrocytes; however, when triamcinoloned rats and those animals treated with only the highest dose levels of FX006 or TCA IR for
tress experienced during the conduct of this study. The initial TCA-related inhibition
orticosterone levels measured in FX006-or TCA IR-treated rats are shown as a function
measured by serum corticosterone were a function of systemic TCA concentration and
Fig. 5. Histopathological analysis (mean ± S.E.M.) of rat knee joints at the end of the study following the last of three reactivations of synovitis/arthritis demonstrated joint
degeneration in vehicle-treated control animals. Treatment with a single IA injection of FX006 improved joint scores signiﬁcantly (P  0.05 KruskaleWallis test with Dunn's
multiple comparison post-test at high- and mid-doses compared to vehicle control) as shown above in (A) Composite scores and (B) Individual scores for inﬂammation, cartilage
damage, bone resorption and pannus formation. Treatment with TCA IR resulted in a smaller, non-signiﬁcant improvement.
Fig. 6. These representative micrographs showing toluidine blue stained sections of knee joints taken from a (A) vehicle (B) TCA IR and (C) FX006 (0.28 mg)-treated rats. FX006-
treatment resulted in joint preservation as can be noted in the near-normal joint architecture that was maintained following a single IA injection of 0.28 mg of FX006. Images taken
at 25; note cartilage (large arrow; damaged in the vehicle and TCA IR-treated rats and intact in the FX006-treated rat), pannus formation (small arrow; in vehicle animal only),
bone resorption (arrowhead; in vehicle and TCA IR animals only). S ¼ synovium (note severe inﬂammation in the vehicle and TCA IR-treated animals and normal synovium in the
FX006-treated animal); C ¼ cruciates/intracondylar connective tissue.
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iodoacetate, pericellular staining with Safranin O persisted, and cell
loss is less extensive43. Consistent with these results, in the present
study involving inﬂamed rat joints, FX006 conferred dose-depen-
dent beneﬁt to all joint structures assessed histologically that was
greater than the beneﬁt produced by TCA IR at a dose providing
similar systemic exposure to TCA. In contrast to these and other
data showing that corticosteroids reduce cartilage degradation in
the context of joint inﬂammation, there is evidence in the literature
that repeatedly injected corticosteroids have deleterious effect on
cartilage in normal animal joints as well as in patients in clinical
case reports44e46. Most of these reports describe multiple, frequent
IA steroid injections and none are controlled clinical studies. Given
the protective effect on articular cartilage in models of inﬂamma-
tory arthritis and OA, the relevance of these ﬁndings to the treat-
ment of patients with OA is unclear. In current clinical practice,
corticosteroid injections in the knee of patients with OA are
administered approximately 3million times per year in the US (IMS
PharMetrics Plus database) and are generally well tolerated47.
Further, in a randomized, double-blind, clinical study in OA pa-
tients, IA injection of 40 mg TCA IR every 3 months for 2 years had
no deleterious effect on knee structure vs saline injections as
assessed by radiographic progression of joint space narrowing48.
Finally, no adverse effect on the HPA axis was noted following IA
treatment with FX006. Corticosterone levels in all TCA groups were
signiﬁcantly reduced relative to the vehicle controls shortly after
dosing; however, by day 14, all groups recovered to baseline levels.
Therefore despite prolonged local exposure to TCA with FX006,
systemic concentrations remained low and these therapeutic doses
of FX006 were very well tolerated.
It has been separately demonstrated that relative to TCA IR, the
slow release and absorption of TCA from FX006 produces signiﬁ-
cantly lower systemic exposures to TCA. In multiple studies in rats
and dogs, and even in human OA patients49 it has been noted that
at matched doses, AUC0e∞ for TCA is about half that with IA FX006
than with TCA IR. Further, AUC0e24 and Cmax for TCA have been
observed to be 10e30 lower with FX006 than with TCA IR at
matched doses. In the present study, fewer samples were taken to
minimize stress in these diseased animals but the trends in the PK
parameters from a limited non-compartmental analysis were
consistent with previous studies. At comparable exposures, Cmax for
FX006 at 0.28 mg was 1/10 that for TCA IR at 0.06 mg. Despite the
lower absolute dose, the Cmax in TCA IR-treated animals of 17 ng/mL
was also greater than that reported following the labeled 40 mg IA
dose of Kenalog® in patients29.
In conclusion, the prolonged residence of TCA in the joint
following a single IA dose of FX006 resulted in prolongation of
analgesic effect in this rat model of localized, repeated knee sy-
novitis/arthritis with a signiﬁcant histological improvement in
inﬂammation, pannus formation, cartilage damage and bone
resorption. FX006 had these effects with low systemic exposure to
TCA and without prolonged inhibition of the HPA axis function.
Therefore in patients, especially those sub-groups in whom syno-
vitis/inﬂammation is a major feature, the effect of FX006 can be
expected to be greater and more durable than that of TCA IR in
terms of pain relief as well as joint disease progression, particularly
in the early stages of disease. Importantly, these data with FX006
demonstrate that TCA had no deleterious effect on cartilage as has
been described in other settings, and consistent with other data in
the literature, it actually reduced cartilage damage in this inﬂam-
matory milieu by slowing, arresting or reversing loss of articular
cartilage.
This model was speciﬁcally developed to induce localized,
repeated synovitis/arthritis in knees of rats that would allow
assessment of the efﬁcacy of a single IA injection of an extended-release formulation of TCA. Further, the model was validated by
employing a dose of TCA IR that demonstrates short-term efﬁcacy
similar to what is routinely noted in the clinic. Since only three
reactivations of arthritis/synovitis at 2-week intervals were
possible before the disease became more wide-spread, the
available period of assessment was limited to 32 days. Animals
demonstrating ankle swelling following the second reactivation
were excluded from the third reactivation. Further, blood sam-
pling for plasma TCA measurement was limited to only a few
time points in these animals that were already undergoing
numerous study-related procedures. Therefore the PK parameters
calculated from these concentration-time data are more impre-
cise estimates as compared to more detailed PK assessments that
have been separately performed for both FX006 and TCA IR. The
pain and stress of arthritis in these animals also resulted in more
variable corticosterone measurements as compared to separate
studies in healthy animals. Nonetheless, the objectives of this
study were met and the observations of efﬁcacy of FX006 in
ameliorating pain and improving joint structure were consistent
and reliable.
The efﬁcacy and safety of IA TCA IR has been established in the
clinic for decades. FX006 has the potential to provide superior pain
relief to TCA IR, and in two Phase II studies in patients with OA of
the knee, FX006 has demonstrated local pharmacokinetics consis-
tent with prolonged TCA residence in the joint and a prolonged and
ampliﬁed analgesic effect, relative to a matched dose of TCA IR49,50.
In humans, the slow release of TCA from PLGA microspheres is
expected to provide about 3months of therapeutic TCA levels in the
knee joint with lower systemic exposures to TCA than produced
with 40mg of IA Kenalog®-40, currently widely used in OA patients.
FX006 has the potential not only provide prolonged pain relief and
functional improvement, but also to limit disease progression
without prolonged inhibition of the HPA axis function. FX006 may
constitute a valuable treatment alternative in the expanding pop-
ulation of patients with OA.Author contributions
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